Bookbuilding IPO | ₹740 Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Virupaksha Organics Ltd. on February 12, 2026. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Virupaksha Organics Ltd. IPO is a Book Build Issue of ₹740.00 crores consisting solely of fresh issue of shares with no offer for sale component.
The equity shares are proposed to be listed on NSE and BSE. Axis Capital Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Virupaksha Organics IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | [.] shares (agg. up to ₹740 Cr) |
| Fresh Issue | [.] shares (agg. up to ₹740 Cr) |
| Share Holding Pre Issue | 6,15,31,937 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Mon, Sep 29, 2025 |
| SEBI/Exchange approval received | Thu, Feb 12, 2026 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII Shares Offered | Not less than 15% of the Net Issue |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 1997, Virupaksha Organics is a research-driven Indian pharmaceutical company that makes active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates.
Along with APIs and intermediates, it also provide contract development and manufacturing (CDMO) services to third-party pharma companies. As of March 31, 2025, the company offer 54 products (23 APIs and 31 intermediates) across a wide range of therapeutic areas such as anti-histamines, analgesics, anti-fungals, anti-diabetics, anti-depressants, anti-asthmatics, and more.
It serve over 550 customers in more than 100 countries, including large multinational pharmaceutical companies in the US, Europe, and Japan. Many of its customer relationships span over eight years. The company have also filed 25 drug master files (DMFs) across global markets, including 11 with the USFDA.
The operations are supported by six manufacturing units in Telangana and Karnataka with 223 reactors and a total capacity of 988 KL. The company uses advanced technologies such as flow chemistry, VapourTech reactors, infrared spectroscopy, NMR, mass spectrometry, and x-ray diffraction to maintain product quality and safety.
As of March 31, 2025, the company employed 978 permanent employees.
Competitive strengths
Virupaksha Organics Ltd.'s revenue increased by 6% and profit after tax (PAT) rose by 7% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 952.48 | 696.69 | 601.76 |
| Total Income | 816.52 | 769.45 | 650.65 |
| Profit After Tax | 78.71 | 73.68 | 43.09 |
| EBITDA | 144.24 | 139.18 | 90.91 |
| NET Worth | 456.62 | 275.31 | 209.71 |
| Reserves and Surplus | 415.87 | 238.44 | 197.96 |
| Total Borrowing | 282.23 | 264.35 | 240.85 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirement for capacity expansion at the Expansion Units | 360.00 |
| 2 | Prepayment of all or a portion of certain outstanding borrowings availed by our Company | 195.00 |
| 3 | General corporate purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 21.51% |
| ROCE | 19.12% |
| Debt/Equity | 0.58 |
| RoNW | 17.25% |
| PAT Margin | 9.70% |
| EBITDA Margin | 17.77% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 59.84% |
Lead Manager Reports
Virupaksha Organics IPO is a main-board IPO of 0 equity shares of the face value of ₹10 aggregating up to ₹740 Crores. The issue is priced at To be declared. The minimum order quantity is .
The Virupaksha Organics IPO open and close dates are not available as of now.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Virupaksha Organics IPO using UPI as a payment gateway. Zerodha customers can apply in Virupaksha Organics IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Virupaksha Organics IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Virupaksha Organics IPO dates are not announced. Please check back again after some time.
Virupaksha Organics IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Virupaksha Organics IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Virupaksha Organics IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Virupaksha Organics IPO allotment status.
The Virupaksha Organics IPO listing date is not yet announced. The tentative date of listing is .
